Humacyte's ATEV Beats Standard of Care in Dialysis Access Trial
Event summary
- Humacyte's ATEV met primary endpoint in Phase 3 V012 study, showing 91 more catheter-free days than AV fistula.
- Interim analysis of 80 patients showed statistically significant results (p=0.00070).
- Humacyte plans to file a supplemental BLA with the FDA in the second half of 2026.
- ATEV reduced infection rates to 6 per 100 patient years vs. 23 for AV fistula.
- Study enrollment terminated early due to positive results; 120 patients currently enrolled.
The big picture
Humacyte's ATEV represents a potential paradigm shift in dialysis access, addressing critical unmet needs for female patients and those at risk of AV fistula failure. The positive Phase 3 results position Humacyte to challenge the standard of care, with implications for reducing healthcare costs and improving patient outcomes. The company's ability to secure FDA approval and scale manufacturing will be key to capturing market share in the $50B global dialysis market.
What we're watching
- Regulatory Approval
- Whether the FDA will approve the supplemental BLA in the second half of 2026.
- Market Adoption
- The pace at which Humacyte can commercialize ATEV for dialysis access.
- Competitive Positioning
- How ATEV's superior outcomes will affect market share against existing dialysis access methods.
Related topics